Last reviewed · How we verify
AR101 - Peanut protein capsule
AR101 - Peanut protein capsule is a oral immunotherapy Biologic drug developed by Aimmune Therapeutics, Inc.. It is currently in Phase 2 development for Peanut allergy.
AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts.
AR101 works by desensitizing the immune system to peanut protein, allowing individuals with peanut allergies to safely consume peanuts. Used for Peanut allergy.
At a glance
| Generic name | AR101 - Peanut protein capsule |
|---|---|
| Sponsor | Aimmune Therapeutics, Inc. |
| Drug class | oral immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
AR101 is an oral immunotherapy that uses a gradual exposure approach to increase tolerance to peanut protein. This is achieved by administering increasing doses of peanut protein to patients over time, allowing their immune systems to adapt and reduce their allergic response.
Approved indications
- Peanut allergy
Common side effects
- Gastrointestinal symptoms
- Allergic reactions
Key clinical trials
- Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) (PHASE2)
- Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (PHASE3)
- Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PHASE3)
- Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (PHASE2)
- Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study (PHASE2)
- Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (PHASE3)
- ARTEMIS Peanut Allergy In Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AR101 - Peanut protein capsule CI brief — competitive landscape report
- AR101 - Peanut protein capsule updates RSS · CI watch RSS
- Aimmune Therapeutics, Inc. portfolio CI
Frequently asked questions about AR101 - Peanut protein capsule
What is AR101 - Peanut protein capsule?
How does AR101 - Peanut protein capsule work?
What is AR101 - Peanut protein capsule used for?
Who makes AR101 - Peanut protein capsule?
What drug class is AR101 - Peanut protein capsule in?
What development phase is AR101 - Peanut protein capsule in?
What are the side effects of AR101 - Peanut protein capsule?
Related
- Drug class: All oral immunotherapy drugs
- Manufacturer: Aimmune Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Peanut allergy
- Compare: AR101 - Peanut protein capsule vs similar drugs
- Pricing: AR101 - Peanut protein capsule cost, discount & access